We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

2 FTSE 250 dividend stocks I’d buy and hold for 25 years

Royston Wild zeroes in on two terrific FTSE 250 (INDEXFTSE: MCX) income heroes that could make you richer.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

I spend a whole heap of time scouring the FTSE 250 for top-notch dividend shares to present to you. I always go in looking for stocks that investors will feel comfortable enough to buy and hold for a minimum of about five years, but there’s plenty out there whose bright futures extend far beyond such a timeframe.

Take Dechra Pharmaceuticals (LSE: DPH), for example. It’s fallen seriously out of favour in recent weeks amid concerns of rising competition in the animal healthcare segment, the company reporting in early September that “the veterinary market is seeing faster change than at any time in its history.”

Should you buy Dechra Pharmaceuticals Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Medicines demand for comfort and agricultural animals is heading through the roof, as underlined by Dechra reporting another double-digit-percentage revenues rise (at constant currencies) last month.

And I think that you can rely on the healthcare mammoth (which has spent a fortune to boost its geographical handprint and bolster its drugs pipeline through shrewd acquisitions) to keep impressing, despite the increased competition thanks to its fizzy M&A programme. Indeed, earlier this month, Dechra shelled out £37.8m on Laboratorios Vencofarma do Brasil, a specialist in developing products for livestock care in the fast-growing regions of South America.

It’s no surprise, to me at least, to see City brokers forecasting another hefty earnings rise in the current year, the 12 months to June 2019. A 12% increase is predicted and this leads to expectations that dividends will keep rising at an impressive rate, too — last year’s  payout of 25.5p per share is forecast to rise to 28.2p, resulting in a yield of 1.2%.

This reading, or Dechra’s forward P/E ratio of 26.5 times, may not suit all investors. In my opinion, though, the probability that it will keep delivering strong profits and dividend growth in the years — nay, decades — ahead still makes it a terrific share to stock up on today.

Out of fashion

The investment community has fallen out of love with Superdry (LSE: SDRY) too, on account of less-than-impressive financials last time out.

The fashion brand declared earlier in October that unusually hot weather in Europe and the US has dented demand for its autumn/winter clothing lines and that, as a result, full-year profits would take a hit to the tune of £10m.

Stock pickers have been a little too quick to cast Superdry adrift, though, as its long-term profits outlook remains exceptional. It is investing vast sums in its product lines to increase the range of highly-desirable items that it supplies, while it also continues to spend heavily on expanding its global store network and improving its increasingly-critical online channel.

Like Dechra, Superdry is no stranger to lifting the dividend at a solid pace, and although a 6% profits drop is forecast for the year to April 2019, the annual ordinary payout is predicted to grow to 33p per share from 31.2p last year, resulting in a chunky 4.1% yield. Further special dividends may also be in the offing given the rate at which Superdry is churning out cash.

At current prices Superdry trades on a forward P/E ratio of just 9.2 times, and this makes it too good to miss in my opinion.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Superdry. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

If a stock market crash is coming, history says this simple move makes money

What to do in a stock market crash? Don't panic for a start and then consider buying a high-quality share…

Read more »

Google office headquarters
Investing Articles

Alphabet stock has fallen from $404 to $318. Time to consider buying?

After a 21% fall, Alphabet stock is now a lot cheaper than it was back in May. Is it time…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

SpaceX stock just crashed 50%! Here’s what I’m doing

After all the excitement about that IPO, Harvey Jones says SpaceX stock has lost half its value. Are we suddenly…

Read more »

Space satellite orbiting the earth.
Investing Articles

By mid-2027, analysts expect $3,000 in Tesla stock to be worth…

Tesla stock has taken a backseat to AI chip names recently and this is reflected in its share price. Is…

Read more »

Investing Articles

Is Raspberry Pi stock a future Nvidia?

Are there any similarities between Raspberry Pi and Nvidia? And even if there are, does this make the FTSE 250…

Read more »

piggy bank, searching with binoculars
Investing For Beginners

Down 25% in a week and at 52-week lows, is this UK share now a bargain?

Jon Smith points out a UK share that has been beaten down recently, but could now be undervalued with an…

Read more »

Investing Articles

My favourite FTSE 100 growth stock jumped another 6% today but still trades at a 17% discount!

Harvey Jones is a massive fan of this growth stock and is thrilled to see its shares are climbing again…

Read more »

Elderly, couple hiking and bird watching with adventure outdoor, hike together and fitness for active lifestyle. Nature, trekking and senior man pointing and woman with binocular, freedom and travel.
Investing Articles

Here’s what £5,000 in a best-buy Cash ISA could be worth in July 2027

Harvey Jones says there are some decent Cash ISA rates on the market today but in the longer run stocks…

Read more »